Placebo rates in randomized clinical trials of ulcerative colitis: an individual patient data meta-analysis

Abstract Background and Aims We assessed placebo rates and associated factors using individual patient data (IDP) from randomized clinical trials (RCTs) in ulcerative colitis (UC). Methods We conducted an IPD meta-analysis using Vivli and Yale University Open Data Access data-sharing platforms. Phase 2 and 3 RCTs of advanced biologics in adults with moderate-to-severe UC published since 2010 were included. Pooled placebo rates and 95% CIs were estimated using one- and two-stage meta-analytical approaches. Significant patient-level factors (P < .05) were identified using regression analyses. Primary outcomes were clinical response and remission. Results Data were available for 1703 patients from nine studies. For induction trials, overall placebo response and remission rates were 33% (95% CI 29%-38%) and 9% (95% CI 7%-11%). Overall placebo response and remission rates in maintenance trials were 28% (95% CI 18%-41%) and 14% (95% CI 9%-20%). A lower body mass index reduced the odds of placebo response and remission, while higher baseline albumin levels and left-sided (compared to extensive) UC increased the odds of these outcomes. A 1-point increase in the Mayo Clinic Score (MCS) and adapted MCS was associated with a 26% and 27% reduction in odds of clinical remission. For induction trials, prior biologic exposure was associated with lower odds of response and remission. Multicenter trials have lower placebo effects than single-center trials. Conclusions These results enable future trials to incorporate design elements that reduce placebo rates as well as a precise benchmark for expected rates in clinical trials that do not include placebo.

• Publication year

  2025

• Venue

  Journal of Crohn's & Colitis

• Publication date

  2025-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/ecco-jcc/jjaf191PMID 41206929PMCID 12668678
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of the FDA and EMA guidance on drug development in ulcerative colitis: an expert panel review

  2025cited by this paper
• Placebo rates in Crohn's disease randomized clinical trials: An individual patient data meta-analysis.

  2024cited by this paper
• Differential efficacy of medical therapies for ulcerative colitis according to disease extent: patient-level analysis from multiple randomized controlled trials

  2024cited by this paper
• Toward Patient Centricity: Why Do Patients With Inflammatory Bowel Disease Participate in Pharmaceutical Clinical Trials? A Mixed-Methods Exploration of Study Participants

  2024cited by this paper
• Review article: Externally derived control arms—An opportunity for clinical trials in inflammatory bowel disease?

  2023cited by this paper
• Two‐stage or not two‐stage? That is the question for IPD meta‐analysis projects

  2023cited by this paper
• Application of Bayesian approaches in drug development: starting a virtuous cycle

  2023cited by this paper
• Factors predicting clinical and endoscopic remission with placebo therapy in East Asian patients with ulcerative colitis: a systematic review and meta-analysis

  2022cited by this paper
• The placebo response rate and nocebo events in obesity pharmacological trials. A systematic review and meta-analysis

  2022cited by this paper
• Predictors of Placebo Induction Response and Remission in Ulcerative Colitis.

  2022cited by this paper
• Placebo rates in randomized controlled trials of proctitis therapy: A systematic review and meta-analysis.

  2022cited by this paper
• Placebo effect on progression and regression in NASH: Evidence from a meta‐analysis

  2022cited by this paper
• Systematic review and Meta-analysis: Clinical, Endoscopic, Histologic and Safety Placebo Rates in Induction and Maintenance trials of Ulcerative Colitis.

  2021cited by this paper
• Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment

  2021cited by this paper
• The Placebo and Nocebo Responses in Clinical Trials in Inflammatory Bowel Diseases

  2021cited by this paper
• Placebos and the Placebo Effect in Drug Trials.

  2019cited by this paper
• Correction: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study

  2019cited by this paper
• Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study)

  2017cited by this paper
• Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis.

  2017cited by this paper
• Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis.

  2016cited by this paper
• Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement.

  2015cited by this paper
• Randomised clinical trial: a placebo‐controlled study of intravenous golimumab induction therapy for ulcerative colitis

  2015cited by this paper
• Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.

  2014cited by this paper
• Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis.

  2014cited by this paper
• Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis

  2013cited by this paper
• Vedolizumab as induction and maintenance therapy for ulcerative colitis.

  2013cited by this paper
• Single-center trials tend to provide larger treatment effects than multicenter trials: a systematic review.

  2013cited by this paper
• Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

  2011cited by this paper
• Single-Center Trials Show Larger Treatment Effects Than Multicenter Trials: Evidence From a Meta-epidemiologic Study

  2011cited by this paper
• The placebo is powerful: estimating placebo effects in medicine and psychotherapy from randomized clinical trials.

  2005cited by this paper
• Meta-analysis of individual patient data from randomized trials: a review of methods used in practice

  2005cited by this paper
• Measuring inconsistency in meta-analyses

  2003cited by this paper
• Quantifying heterogeneity in a meta‐analysis

  2002cited by this paper
• A multilevel model framework for meta-analysis of clinical trials with binary outcomes.

  2000cited by this paper

• No citing papers are available for this paper.